Moderna, Inc.
NASDAQMRNA arrives at its August 6 earnings report with short sellers firmly positioned, options skewing to the most defensive level of the past year, and a stock down 31% in a month — a setup that frames the print as a pivotal test for a company trying to prove its mRNA platform can generate durable revenue beyond COVID vaccines. The most acute signal heading into the report is options…
Snapshot as of 6 Aug 2026
A new long-form analysis for MRNA this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumMRNA arrives at its August 6 earnings report with short sellers firmly positioned, options skewing to the most defensive level of the past year, and a stock down 31% in a month — a setup that frames the print as a…
Moderna has now rallied 68% in a month to $79.77 — yet the Street's price targets remain well below the current price, and 15.6% of the free float is still short. The analyst picture this week captures the tension…
Moderna has now added 20% in a single week and 54% over the past month — yet the short base has barely moved, and the bears who built positions at much lower prices are still holding. The central tension is familiar…
Moderna has now re-rated 43% in a single month, yet the short base has not just survived the rally — it has grown through it. Short interest has climbed to 15.4% of the free float, edging up roughly 3% over the past…
Moderna has delivered one of its strongest weekly performances of the year, up 16% to $55.40, yet short sellers have barely flinched — and that contradiction is the story this week. Short interest is elevated and…
Moderna heads into Wednesday's first-quarter release with analysts freshly raising targets — yet none willing to turn bullish. The most striking feature of the run-up is the breadth and speed of analyst target upgrades…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MRNA — free to start on ORTEX.
Sign up for free →Open MRNA on ORTEX